Stem cell therapy for critical limb ischemia: What can we learn from cell therapy for chronic wounds?

Vascular

Volumn 20, Issue 5, 2012, Pages 284-289

  Jadlowiec, Caroline ^a,b   Brenes, Robert A ^a,c   Li, Xin ^a   Lv, Wei ^a   Protack, Clinton D ^a   Collins, Michael J ^a   Dardik, Alan ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c ST MARY S HOSPITAL   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Cell therapy; Platelet derived growth factor; Platelet rich plasma; Therapeutic angiogenesis; Wound healing

Indexed keywords

BECAPLERMIN; FIBROBLAST GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTICLE; ARTIFICIAL SKIN; BILAYERED BIOENGINEERED SKIN SUBSTITUTE; BIOENGINEERING; CELL DIFFERENTIATION; CHRONIC WOUND; CRITICAL LIMB ISCHEMIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KERATINOCYTE; MONOTHERAPY; NEONATAL FIBROBLAST DERIVED DERMIS; PARACRINE SIGNALING; PRIORITY JOURNAL; SKIN FIBROBLAST; SKIN GRAFT; STEM CELL TRANSPLANTATION; THROMBOCYTE RICH PLASMA; TISSUE ENGINEERING; TISSUE REPAIR; WOUND CARE; WOUND CLOSURE; WOUND HEALING;

ANIMALS; CHRONIC DISEASE; CRITICAL ILLNESS; HUMANS; ISCHEMIA; LOWER EXTREMITY; NEOVASCULARIZATION, PHYSIOLOGIC; SKIN; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84868015069     PISSN: 17085381     EISSN: 1708539X     Source Type: Journal    
DOI: 10.1258/vasc.2011.201206     Document Type: Article

References (35)

1. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275: 964-7
2. Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active hypoxia-inducible factor-1 transgene as a therapeutic strategy in no-option critical limb ischemia patients phase I dose-escalation experience. Circulation 2007;10:1234-43
3. Tateishi-Yuyama E, Hiroaki M, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002;360:427-35
4. Diehm C, Trampisch H, Haberl R, et al. Prognosis of patients with asymptomatic versus symptomatic peripheral arterial disease: 3-year results of the get ABI study. Vasc Med 2007; 12:2141-8
5. Heil M, Ziegelhoeffer T, Mees B, Schaper W. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ Res 2004; 94:573-4
6. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010;209:10-7
7. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7
8. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93
9. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of dermagraft in improving the healing of chronic diabetic foot ulcers. Diabetes Care 2003;26:1701-5
10. Mansbridge J, Liu K, Pinney E, Patch R, Ratcliffe A, Naughton G. Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabetes Obes Metab 1999;1:265-79
11. Pinnney E, Liu K, Sheeman B, Mansbridge J. Human three-dimensional fibroblasts cultures express angiogenic activity. J Cell Physiol 2000;183:74-82
12. Lamme EN, van Leeuwen RTJ, Jonker A, van Marle J, Middelkoop E. Living skin substitutes: survival and function of fibroblasts seeded in a dermal substitute in experimental wounds. J Invest Dermatol 1998;111:989-95
13. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs 1997;21:1203-10
14. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678-85
15. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004;62:489-96
16. Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med 2010;83:1-9
17. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and Il-1alpha. J Cell Physiol 1996;166: 585-92
18. Parenteau NL, Nolte CM, Bilbo P, et al. Epidermis generated in vitro: practical considerations and applications. J Cell Biochem 1991;45:245-51
19. Marston WA. Dermagraft®, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer. Expert Rev Med Devices 2004;1:21-31
20. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001;104:1046-52
21. Redler LH, Thompson SA, Hsu SH, Ahmad CS, Levine WN. Platelet-rich plasma therapy: a systematic literature review and evidence for clinical use. Phys Sportsmed 2011;39:42-51
22. Fuchs S, Baffour R, Zhou Y. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 2001;37:1726-32
23. Mansbridge J. Commercial considerations in tissue engineering. J Anat 2006;209:527-32
24. Falnga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogenic cultured human skin equivalent. Arch Dermatol 1998;134:293-300
25. Hansbrough JF, Morgan J, Greenleaf G, Parikh M, Nolte C, Wilkins L. Evaluation of Graftskin composite grafts on full-thickness wounds on athymic mice. J Burn Care Rehabil 1994;15:346-53
26. Shukla VK, Tiwary SK, Barnwal S, Gulati AK, Pandey SS. Effect of autologous epidermal cell suspension transplantation in chronic nonhealing wounds: a pilot study. Can J Surg 2010;53:6-10
27. McKay IA, Leigh IM. Epidermal cytokines and their role in cutaneous wound healing. Br J Derm 1992;124:513-8
28. Navsaria HA, Myers SR, Leigh IM, McKay IA. Culturing skin in vitro for wound therapy. Trends Biotech 1995;13:91-100
29. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-5
30. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with neuropathic diabetic ulcers. Diabetes Care 1998;21:822-7
31. Robson MC, Thomason A, Pierce GF, et al. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992;339:23-5
32. Taylor DW, Petrera M, Hendry M, Theodoropoulos JS. A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries. Clin J Sport Med 2011;21:344-52
33. Gaweda K, Tarczynska M, Krzyzanowski W. Treatment of achilles tendinopathy with platelet-rich plasma. Int J Sports Med. 2010;31:577-83
34. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006;34: 1774-8
35. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004;114: 1502-8